

Short-Acting Beta2 Agonists (SABA)

SALBUTAMOL
Respigen® **SalAir®** **Ventolin®**

 100 mcg
 Aerosol inhaler

TERBUTALINE
Bricanyl®


 250 mcg
 Turbuhaler®

Short-Acting Muscarinic Antagonists (SAMA)


IPRATROPIUM
Atrovent®


 20 mcg
 Aerosol inhaler


Combination SABA + SAMA


SALBUTAMOL + IPRATROPIUM
Duolin HFA®

 100 mcg/20 mcg
 Aerosol inhaler

Inhaled Corticosteroids (ICS)

FLUTICASONE propionate
Flixotide®

 50 mcg 125 mcg 250 mcg
 Aerosol inhaler


BUDESONIDE
Pulmicort®

 100 mcg 200 mcg 400 mcg
 Turbuhaler®


BECLOMETHASONE dipropionate
Beclazone®

 50 mcg 100 mcg 250 mcg

Qvar® (ultrafine particle)

 50 mcg 100 mcg

Note: Beclazone® and Qvar® are not dose equivalent and are not interchangeable

Combination Inhaled Corticosteroids (ICS) + Long-Acting Beta2 Agonists (LABA)

FLUTICASONE propionate + SALMETEROL
Seretide®

 50/25 125/25 250/25
 Aerosol inhaler


FLUTICASONE propionate + VILANTEROL
Breo Ellipta®

 100 mcg/25 mcg
 Dry powder inhaler


**100/50 and 250/50 accuhaler only funded if no more than 2 doses per day*


FLUTICASONE furoate + VILANTEROL
Breo Ellipta®

 100 mcg/25 mcg
 Dry powder inhaler

Note: 200 mcg/25 mcg strength available but not funded

BUDESONIDE + FORMOTEROL
Vannair®

 100/6 200/6
 Aerosol inhaler

Symbicort®

 100/6 200/6 400/12*
 Turbuhaler®

DuoResp Spiromax®

 200/6 400/12*
 Dry powder inhaler

**Symbicort 400/12 and DuoResp Spiromax 400/12 only funded if no more than 2 doses per day*

Note: Symbicort 100/6, 200/6 and DuoResp Spiromax 200/6 are currently approved for Anti-Inflammatory Reliever (AIR) therapy. Vannair 100/6 and 200/6 is approved for maintenance use, but its use in AIR therapy is an unapproved indication.

Long-Acting Beta2 Agonists (LABA)

SALMETEROL

Serevent®



25 mcg
Aerosol inhaler

50 mcg
Accuhaler®

FORMOTEROL (eformoterol)

Oxis®



6 mcg
Turbuhaler®

Foradil®



12 mcg
Aerolizer device®

INDACATEROL

Onbrez Breezhaler®



150 mcg 300 mcg
Breezhaler®

Long-Acting Muscarinic Antagonists (LAMA)

TIOTROPIUM

Spiriva®



18 mcg
Handihaler®

Spiriva
Respimat®



2.5 mcg
Fine mist inhaler

UMECLIDINIUM

Incruse
Ellipta®



62.5 mcg
Dry powder inhaler

GLYCOPYRRONIUM

Seebri®
Breezhaler®



50 mcg
Breezhaler®

Funded by Endorsement: LAMA inhaler is subsidised only for patients who have been diagnosed as having COPD using spirometry if spirometry is possible, and the prescription is endorsed accordingly (i.e. COPD documented as indication on prescription).
Not subsidised if patient is also receiving treatment with another subsidised LAMA.

Combination Long-Acting Muscarinic Antagonists (LAMA) + Long-Acting Beta2 Agonists (LABA)

TIOTROPIUM + OLODATEROL

Spiolto
Respimat®



2.5 mcg/2.5 mcg
Fine mist inhaler

UMECLIDINIUM + VILANTEROL

Anoro
Ellipta®



62.5 mcg/25 mcg
Dry powder inhaler

GLYCOPYRRONIUM + INDACATEROL

Ultibro®
Breezhaler®



50 mcg/110 mcg
Breezhaler®

Funded via Special Authority: LAMA + LABA inhaler is subsidised only for patients who have been stabilised on a LAMA and the prescriber considers that the patient would receive additional benefit from switching to a combination product. Not subsidised if patient is also receiving treatment with a combination ICS and LABA.

Funded Not funded Partially funded

Funded by endorsement Funded by Special Authority

Spacers are available free to those who need them on a Practitioners Supply Order (PSO).

Contact Manatū Hauora Ministry of Health for an order form on 0800 353 2425.

Everyone should have an action plan. Find a range of management plans at asthmafoundation.org.nz

ARFNZ would like to acknowledge the Clinical Pharmacy Department, Counties Manukau Health, for the source template.